الصفحة الرئيسية>>Signaling Pathways>> Tyrosine Kinase>> ROR>>RORγt Inverse agonist 6

RORγt Inverse agonist 6

رقم الكتالوجGC62623

RORγ ؛ t ناهض معكوس 6 (مركب 43) هو ناهض عكسي RORγt لدراسة أمراض المناعة الذاتية التي يحركها Th17.

Products are for research use only. Not for human use. We do not sell to patients.

RORγt Inverse agonist 6 التركيب الكيميائي

Cas No.: 1887161-80-9

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
537٫00
متوفر
1mg
173٫00
متوفر
5mg
432٫00
متوفر
10mg
720٫00
متوفر
25mg
1485٫00
متوفر
50mg
2340٫00
متوفر
100mg
3600٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

RORγt Inverse agonist 6 (compound 43) is a RORγt inverse agonist for the study of Th17-driven autoimmune diseases. RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in vivo[1].

RORγt Inverse agonist 6 (compound 43) suppresses IL-17A gene expression by IL-23 stimulation in a mouse pharmacodynamics model[1].RORγt Inverse agonist 6 (compound 43) exhibits improved drug exposure (mouse AUC: 1289 ng•h/mL at 1 mg/kg, po)[1].RORγt Inverse agonist 6 (compound 43, 30 mg/kg, po, b.i.d) inhibits the expression level of IL-17A by 59% compared to the vehicle after the oral administration at the tested dose[1].

[1]. Sato A, et al. Design and Synthesis of Conformationally Constrained RORγt Inverse Agonists. ChemMedChem. 2019 Oct 28.

مراجعات

Review for RORγt Inverse agonist 6

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RORγt Inverse agonist 6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.